Total Payments
$20,067
2022 Payments
$5,262
Companies
66
Transactions
550
Medicare Patients
492
Medicare Billing
$66,089
Payment Breakdown by Category
Food & Beverage$15,771 (78.6%)
Consulting$3,075 (15.3%)
Education$1,221 (6.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,771 | 534 | 78.6% |
| Consulting Fee | $3,075 | 2 | 15.3% |
| Education | $1,221 | 14 | 6.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $2,381 | 35 | $0 (2022) |
| Global Blood Therapeutics, Inc. | $2,139 | 4 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,894 | 74 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $1,235 | 29 | $0 (2022) |
| Merck Sharp & Dohme LLC | $1,049 | 40 | $0 (2022) |
| Lilly USA, LLC | $926.35 | 33 | $0 (2022) |
| PFIZER INC. | $831.66 | 36 | $0 (2022) |
| Incyte Corporation | $808.69 | 20 | $0 (2022) |
| Celgene Corporation | $654.12 | 16 | $0 (2022) |
| Astellas Pharma US Inc | $649.99 | 15 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $5,262 | 103 | Global Blood Therapeutics, Inc. ($2,092) |
| 2021 | $3,537 | 111 | Janssen Biotech, Inc. ($683.60) |
| 2020 | $1,286 | 43 | Novartis Pharmaceuticals Corporation ($176.05) |
| 2019 | $3,194 | 124 | Lilly USA, LLC ($345.39) |
| 2018 | $2,461 | 74 | Novartis Pharmaceuticals Corporation ($385.40) |
| 2017 | $4,326 | 95 | Janssen Biotech, Inc. ($1,062) |
All Payment Transactions
550 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2022 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Oncology | ||||||
| 10/13/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: Oncology | ||||||
| 10/05/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2022 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO, RETEVMO | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: Oncology | ||||||
| 10/04/2022 | Organon LLC | ONTRUZANT (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: TRASTUZUMAB | ||||||
| 09/29/2022 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Hematology | ||||||
| 09/28/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: ONCOLOGY | ||||||
| 09/28/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA, WELIREG | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Iron Deficiency Anemia | ||||||
| 09/13/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Hematology | ||||||
| 09/12/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.05 | General |
| Category: Hematology | ||||||
| 08/23/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, PAXLOVID | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: ONCOLOGY | ||||||
| 08/10/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2022 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Oncology | ||||||
| 08/04/2022 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: ONCOLOGY | ||||||
| 08/03/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 08/02/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 7 | 173 | 224 | $110,589 | $29,340 |
| 2021 | 10 | 229 | 269 | $99,031 | $28,576 |
| 2020 | 3 | 90 | 126 | $36,606 | $8,173 |
Total Patients
492
Total Services
619
Medicare Billing
$66,089
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 33 | $22,473 | $6,078 | 27.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $18,840 | $4,769 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 36 | $16,056 | $4,328 | 27.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 44 | $15,444 | $4,250 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 25 | $15,850 | $4,217 | 26.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 48 | $15,360 | $3,892 | 25.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $6,566 | $1,805 | 27.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 38 | 41 | $13,663 | $4,076 | 29.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 21 | $13,944 | $4,028 | 28.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 27 | 27 | $12,231 | $3,405 | 27.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 26 | $11,414 | $3,299 | 28.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $11,400 | $3,283 | 28.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $9,216 | $2,653 | 28.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 26 | $8,086 | $2,334 | 28.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 44 | 53 | $6,848 | $1,933 | 28.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 22 | 26 | $6,162 | $1,789 | 29.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 18 | $6,066 | $1,776 | 29.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 46 | 73 | $18,483 | $3,780 | 20.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 25 | 28 | $8,573 | $2,787 | 32.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 25 | $9,550 | $1,606 | 16.8% |
About Dr. Lech Dabrowski, MD
Dr. Lech Dabrowski, MD is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780798553.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lech Dabrowski, MD has received a total of $20,067 in payments from pharmaceutical and medical device companies, with $5,262 received in 2022. These payments were reported across 550 transactions from 66 companies. The most common payment nature is "Food and Beverage" ($15,771).
As a Medicare-enrolled provider, Dabrowski has provided services to 492 Medicare beneficiaries, totaling 619 services with total Medicare billing of $66,089. Data is available for 3 years (2020–2022), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Brooklyn, NY
- Active Since 08/18/2006
- Last Updated 10/12/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1780798553
Products in Payments
- OXBRYTA (Drug) $2,139
- IMBRUVICA (Drug) $1,841
- KEYTRUDA (Biological) $1,013
- DARZALEX (Biological) $695.09
- OPDIVO (Biological) $632.57
- KISQALI (Drug) $479.06
- Revlimid (Drug) $406.26
- ZEJULA (Drug) $344.01
- JAKAFI (Drug) $331.70
- VERZENIO (Drug) $321.88
- SUTENT (Drug) $320.08
- NINLARO (Drug) $305.32
- XTANDI (Drug) $294.07
- Kyprolis (Drug) $287.63
- Xofigo (Drug) $260.65
- Imbruvica (Drug) $260.63
- JEVTANA (Drug) $250.24
- Tavalisse (Drug) $233.30
- ADAKVEO (Biological) $215.06
- INJECTAFER (Drug) $212.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brooklyn
Perry Cook, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Yiwu Huang, Md, MD
Hematology & Oncology — Payments: $268,275
Hematology & Oncology $268,275
Dr. Ilya Blokh, M.d, M.D
Hematology & Oncology — Payments: $191,276
Hematology & Oncology $191,276
Songchuan Guo, M.d, M.D
Hematology & Oncology — Payments: $106,907
Hematology & Oncology $106,907
Yiqing Xu, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $51,145
Hematology & Oncology $51,145
Dr. Azriel Hirschfeld, M.d, M.D
Hematology & Oncology — Payments: $48,699
Hematology & Oncology $48,699